+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
P

Actively Recruiting

Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.

All AgesAll GendersPhase 3
629 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how different types of casts affect satisfaction and pain in children with upper or lower extremity fractures. The study compares plain white casts, colored casts chosen by the child, and casts decorated with custom art like drawings and glitter. It aims to understand how cast customization influences patient and parent satisfaction and perceived pain during healing. Participants will be randomly assigned to one of three groups receiving a neutral white cast, a cast wrapped in the participants chosen color, or a cast with custom artwork. The casts are applied either in the emergency department or during follow-up visits, including after surgery if needed. The length of casting depends on the fracture type and healing progress monitored through radiographs. Children will be assessed at multiple time points after injury, including 0-2 weeks, 4-6 weeks, and 8-12 weeks if needed. Researchers will collect satisfaction scores using a visual analog scale and pain data using a pediatric pain questionnaire. Clinical and radiographic data will also be reviewed to monitor healing. The total participation duration is based on the healing time required for the fracture.

Age: 5Years - 18YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
P

Actively Recruiting

Researchers are studying how adding dinutuximab to intensive multimodal therapy may affect treatment outcomes in children with newly diagnosed high-risk neuroblastoma. This phase III trial compares standard chemotherapy and surgery to a combination of chemotherapy plus dinutuximab during Induction therapy. The study also evaluates the effects of subsequent treatments including stem cell transplantation, radiation, and immunotherapy, aiming to improve event-free survival and overall survival for these patients. Participants receive multiple cycles of Induction chemotherapy involving drugs such as cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. They are randomly assigned to either standard chemotherapy or chemoimmunotherapy with dinutuximab. After Induction, patients with good tumor response proceed to Consolidation therapy with two autologous stem cell transplants followed by radiation. Those with poor response receive Extended Induction chemoimmunotherapy. The final Post-Consolidation phase includes dinutuximab and isotretinoin treatments to maintain response. Throughout the study, patients undergo various assessments including blood and urine tests, echocardiograms or MUGA scans, bone marrow biopsies, CT, MRI, I-MIBG, and possibly FDG-PET scans. Researchers monitor response to therapy, adverse events, biomarker expression, and quality of life over time. Follow-up visits occur regularly up to 10 years after enrollment to assess long-term outcomes and safety. The primary measure is event-free survival, with additional outcomes including response rates and overall survival.

Age: 0 - 30YearsAll GendersPhase 3
180 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of rimegepant compared to a placebo as a preventative treatment for children and adolescents aged 6 to under 18 years with episodic migraine. The study focuses on reducing the number of migraine days per month and improving quality of life in this young population. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Pfizer. Participants receive either rimegepant in doses of 75mg or 50mg two 25mg orally disintegrating tablets or a matching placebo with the same dosing options. The study uses a double-blind design over a 12-week treatment phase to compare outcomes. The research also monitors safety and tolerability for up to 72 weeks, including the frequency of liver-related adverse events. During the study, participants will have assessments to record migraine days and severity, use of acute migraine medications, and quality of life using the Pediatric Quality of Life Inventory. Researchers will track safety through ongoing monitoring for adverse effects. The primary measure is the change in mean monthly migraine days over 12 weeks, with additional evaluations during the first 4 weeks and longer-term safety follow-up. Total participation may last up to 72 weeks for safety evaluation.

Age: 6Years - 17YearsAll GendersPhase 3
93 locations
R

Actively Recruiting

Researchers are evaluating whether adding inotuzumab ozogamicin to post-induction chemotherapy and immunotherapy improves outcomes for children and young adults with High-Risk B-cell Acute Lymphoblastic Leukemia B-ALL. This phase III trial also studies patients with mixed phenotype acute leukemia MPAL and B-lymphoblastic lymphoma B-LLy treated with standard acute lymphoblastic leukemia therapy. The study aims to understand if this addition maintains or improves five-year event-free survival and assesses side effects, quality of life, treatment adherence, immune impact, and social factors affecting outcomes. Participants first receive induction therapy with a combination of chemotherapy drugs including vincristine, daunorubicin, methotrexate, and steroids, among others. After induction, patients with high-risk B-ALL and CD22 positive status are randomized into two groups one receiving standard chemo-immunotherapy including blinatumomab Arm D, and the other receiving modified chemo-immunotherapy with inotuzumab ozogamicin replacing parts of consolidation and delayed intensification Arm E. Patients with MPAL and B-LLy receive tailored chemotherapy regimens without inotuzumab. Treatment phases include consolidation, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance therapy over up to two years. Throughout the study, participants undergo blood sample collection, bone marrow aspiration and biopsy, and imaging studies such as CT, MRI, PET, and bone scans as appropriate. Researchers monitor treatment effects, adverse events, and quality of life using patient-reported outcomes. After completing treatment, participants are followed for up to five years with regular visits to assess disease status, survival, and long-term effects.

Age: 365Days - 25YearsAll GendersPhase 3
231 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are comparing how long pain relief lasts between two types of local anesthetic combinations used during erector spinae plane blocks for patients undergoing mastectomy surgery for breast cancer. This trial aims to see if adding dexmedetomidine to bupivacaine provides longer or more effective pain control than using liposomal bupivacaine with bupivacaine alone. The study measures differences in pain relief duration and the amount of opioid pain medication needed after surgery. Participants will receive an erector spinae plane block guided by ultrasound performed by the Acute Pain Service team. Patients are randomly assigned by month to receive either bupivacaine 0.25% with liposomal bupivacaine or bupivacaine 0.25% with dexmedetomidine. The local anesthetic is delivered using a needle placed under direct visualization into the erector spinae plane, with doses adjusted by patient weight and surgical side. All patients receive 10 mg intravenous dexamethasone after anesthesia induction. During the hospital stay, pain scores and opioid use in morphine equivalents are recorded every 6 hours starting in the recovery area until discharge. After discharge, participants are contacted at 72 hours to report daily pain scores and opioid tablet use since leaving the hospital. The primary outcome is the density and duration of pain relief over 96 hours, while secondary measures include total oral opioid consumption during the same period.

Age: 18Years +All GendersPhase 4
1 location
L

Actively Recruiting

Researchers are conducting a long-term follow-up study to track and collect ongoing health information from patients who have participated in Childrens Oncology Group COG studies. This observational study aims to improve understanding of long-term effects of cancer treatment and enhance patient quality of life by maintaining regular contact over many years. Participants receive an introductory packet within three months of enrollment, which includes forms to update their contact and health status. They can respond via prepaid mail, secure online forms, or a toll-free phone number. After the initial contact, the Long-Term Follow-Up Center LTFC will reach out annually to gather updated information on health, disease status, and any cancer therapies received. During the study, participants are asked to complete response and quality of life questionnaires. Researchers collect data on patient location, health status, treatment exposure, and protocol-specific outcomes. This ongoing monitoring may continue for up to 20 years, helping to maintain current patient information and support future cancer research and care improvements.

All AgesAll Genders
164 locations

1-10 of 15

1